# Opevesostat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/opevesostat

> The next catalyst for opevesostat, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Nov 2027 to Feb 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | opevesostat |
| Codes | MK-5684 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Malignant Neoplasm](https://sec-api.dev/indications/malignant-neoplasm), [Prostate Cancer Metastatic](https://sec-api.dev/indications/prostate-cancer-metastatic), [Metastatic Castration-resistant Prostate Cancer (mCRPC)](https://sec-api.dev/indications/metastatic-castration-resistant-prostate-cancer-mcrpc) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Malignant Neoplasm.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06979596 (A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06979596

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Malignant Neoplasm.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06979596 (A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06979596

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06136650 (A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06136650

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06136650 (A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06136650

### Nov 2028 to Feb 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Prostate Cancer Metastatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06136624 (Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06136624

### November 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Prostate Cancer Metastatic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06136624 (Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT06136624

Calendar months: [November 2027](https://sec-api.dev/fda-calendar/2027-11), [May 2028](https://sec-api.dev/fda-calendar/2028-05), [November 2028](https://sec-api.dev/fda-calendar/2028-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/opevesostat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Opevesostat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/opevesostat

```bibtex
@misc{secapidev_pdufa_opevesostat_20261116,
  title        = {Opevesostat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/opevesostat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_opevesostat_20261116","title":"Opevesostat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/opevesostat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
